Avid Bioservices Inc (CDMO)

[Fire Fox]

Than you FTM. Very interesting that there will be a poster on the HER2- breast cancer IST even though ClinicalTrials.gov says today that "This study is currently recruiting."

There are only 14 patients in the total trial population. I can't imagine why ASCO would accept a poster on a trial where only 8 or 10 or 12 patients have completed dosing unless the results for that small population were quite revealing and significant !!!

Why would the principal investigator, Dr. Alison Stopeck at the Univ. of Arizona Cancer Center, publish results before completing the trial unless she had something meaningful to report.

Sounds like Bavi is about to get some buzz in the breast cancer community. :)